Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab study uses donated human tissue to speed up drug screening

NCT ID NCT07047677

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses leftover tissue from surgeries to test how experimental radiolabeled ligands bind to human cells. Researchers aim to create a platform that can quickly assess these agents without needing animal tests. The study involves 300 tissue samples and focuses on measuring how well the ligands stick to their targets.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this platform could help researchers quickly screen new imaging or therapeutic agents on real human tissue, potentially speeding up drug development.
What could go wrong
This is an early, lab-based study using stored tissue samples, not a treatment trial. Results may not predict how the ligands behave in living patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A maximum of 300 human tissue samples will be analyzed over a period of 5 years. This volume allows for the exploration of a variety of tissue types (tumor, inflammatory, healthy) and the testing of several types of radiolabeled molecules, while ensuring adequate reproducibility for each experimental condition. The samples will be provided by the Pathology Department of the Nancy University Hospital, in compliance with regulatory and ethical procedures. Each sample will undergo one or more ex vivo autohistoradiography analyses, without the need for any new samples.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who underwent surgical resection at the Nancy University Hospital after 2019 (Information provided in the welcome booklet or on posters displayed in waiting rooms, mentioning the possible use of data or resection specimens, unless otherwise stated). * No documented objection, in accordance with the MR004 methodology. * Frozen human tissues (slides, blocks, or sections) from surgical resection or biopsy, transmitted by the CRB or the biopathology department. * Samples are fully anonymized before being made available for analysis. Exclusion Criteria: * • Unusable tissue (degraded, insufficient, contaminated, poorly preserved). * Lack of traceability of the material. * Explicit opposition from the patient to the use of their tissue for research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tissue model are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tissue model

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chru Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France